Prévisions

L'objectif de cours moyen des analystes est de 31,19 € (+56,34 %). La médiane est de 33,66 € (+68,72 %).

Acheter	14
Conserver	2
Vendre	0

Actualités Accéder au fil d'actualités

Viridien reports strong order growth; stock jumps after Q2 data

Viridien’s stock rose about 14.7% after Q2 figures following a marked increase in the order backlog in geosciences to USD 306m (up 33% since March). Major project awards from IOCs and NOCs in the Gulf of Mexico, Africa and the Middle East drove the volume; analysts view this as an early sign of broader revenue recovery. The EDA segment reached an adjusted EBITDA margin of 60% and the company confirmed its full-year target of USD 100m net cash flow for 2026. Viridien also filed the interim report with the AMF, providing additional transparency and investor confidence. » Plus sur de.investing.com
Viridian Therapeutics' Lumvoa seen as differentiated treatment for thyroid eye disease, analysts raise targets

Goldman Sachs raised its target for Viridian Therapeutics to $39 and kept a Buy rating, citing Lumvoa's stronger proptosis improvement, promising safety profile and more convenient dosing versus Tepezza. Truist raised its target to $38, reiterated Buy and highlighted Lumvoa's focus on underserved markets, parity pricing and projected significant 2027 revenue with a franchise extension planned for Q1 2027. Viridian's broader pipeline includes Veligrotrug, Elegrobart, an anti‑TSHR program and FcRn inhibitors VRDN‑008 and VRDN‑006. » Plus sur finance.yahoo.com
Viridien expects markedly negative quarterly result and issues annual forecast

Viridien will release results for the quarter ended June 30, 2026 on July 30, 2026; one analyst estimates EPS for the most recent quarter at -1.81 USD per share versus 0.67 EUR a year earlier. Two analysts see quarterly revenue at 237.0 million USD versus 206.7 million EUR in the year-ago quarter. Five analysts forecast an average EPS of 9.94 USD for the current fiscal year and four analysts expect revenue averaging 1.12 billion USD (prior year 948.5 million EUR). » Plus sur finanzen.net

Données financières de l'entreprise

Au dernier trimestre, Viridian Therapeutics Aktie a réalisé un chiffre d'affaires de 248,84 k € et un bénéfice net de -111,38 M €

(EUR)	juin 2026	YoY
Chiffre d'affaires	248,84 k	291,07 %
Bénéfice brut	248,84 k	291,07 %
Bénéfice net	-111,38 M	30,32 %
EBITDA	-104 M	22,45 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	2,26 Md €
Nombre d'actions	113,29 M
Plus haut/bas sur 52 semaines	29,60 € - 11,38 €
Dividendes	Non
Bêta	0,94
Ratio P/E	-6,54
Ratio PEG	-0,73
Ratio P/B	3,76
Ratio P/S	36,76

Profil de l'entreprise

Viridian Therapeutics, Inc. ist ein Biotechnologieunternehmen, das Behandlungen für Patienten entwickelt, die an schweren Krankheiten leiden. Es entwickelt VRDN-001, einen humanisierten monoklonalen Anti-IGF-1R-Antikörper, der sich in der klinischen Phase 1/2 zur Behandlung der Schilddrüsenerkrankung (TED) befindet; VRDN-002, einen IGF-1R-Antikörper, der sich in der klinischen Phase 1 befindet; und VRDN-003, einen therapeutischen Antikörper gegen IGF-1R zur Behandlung von TED. Das Unternehmen war früher als Miragen Therapeutics, Inc. bekannt und änderte im Januar 2021 seinen Namen in Viridian Therapeutics, Inc. Viridian Therapeutics, Inc. wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Waltham, Massachusetts.

Nom	Viridian Therapeutics Aktie
PDG	Stephen F. Mahoney
Siège social	Waltham, ma États-Unis
Site web	viridiantherapeutics.com
Secteur	Santé
Industrie	Équipements et fournitures médicaux
Introduction en bourse	18/06/2014
Employés	252